Complex of Exercise and Glp-1 Receptor Agonist Treatment Reduces Severity of Metabolic Syndrome and Inflammation
Year: 2024
Type: article
Abstract: Identifying and reducing cardiometabolic risks driven by obesity remains a major healthcare challenge [1]. Metabolic syndrome (Metabolic syndrome) is associated with an increased risk of cardiovascular disease, type 2 diabetes, and all-cause mortality [2]. Abdominal obesity is associated with low-grade inflammation and has been proposed as a driver for metabolic syndrome. Body weight loss may improve the factors of Metabolic syndrome [5]; however, weight loss-induced improvements have proven difficult to maintain since substantial weight regain often occurs within the first year [6]. Therefore, investigations of treatment strategies that can maintain, or even reduce, metabolic syndrome, abdominal fat, and low-grade inflammation in currently healthy persons with obesity to prevent future cardiometabolic disease are warranted.
Author: Toshmatova G.A.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7215205268
